Biotech Values

[DewDiligence]

I went back to read Goldman report from Dec 2010. Their estimate of contract change due to other generic entry was well below what MNTA is going to get…

The Goldman analyst who penned the report you just posted is either stupid or disingenuous, probably the latter.

MNTA has publicly disclosed on numerous occasions that the profit-share mode under an AG is the same 45% as under generic exclusivity, so the only question was the profit threshold for the switch from a royalty to the 45% profit share. Thus, the Goldman analyst’s claim that MNTA’s profit share in post-AG profit-share mode was only 30% was a rather extreme case of disinformation.

I’m pretty sure Goldman has been short MNTA during some (perhaps most) of the past year.